Gavriatopoulou, Maria
Chari, Ajai
Chen, Christine
Bahlis, Nizar
Vogl, Dan T. http://orcid.org/0000-0002-2935-2566
Jakubowiak, Andrzej
Dingli, David
Cornell, Robert F.
Hofmeister, Craig C. http://orcid.org/0000-0003-4816-1607
Siegel, David http://orcid.org/0000-0002-3604-2574
Berdeja, Jesus G.
Reece, Donna
White, Darrell
Lentzsch, Suzanne
Gasparetto, Cristina
Huff, Carol Ann
Jagannath, Sundar
Baz, Rachid
Nooka, Ajay K. http://orcid.org/0000-0003-4165-6869
Richter, Joshua
Abonour, Rafat
Parker, Terri L.
Yee, Andrew J.
Moreau, Philippe
Lonial, Sagar
Tuchman, Sascha
Weisel, Katja C.
Mohty, Mohamad
Choquet, Sylvain
Unger, T. J.
Li, Kai
Chai, Yi
Li, Lingling
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Dimopoulos, Meletios Athanasios
Article History
Received: 15 October 2019
Revised: 7 February 2020
Accepted: 10 February 2020
First Online: 24 February 2020
Compliance with ethical standards
:
: MG: honoraria from Amgen, Karyopharm, Takeda, Genesis, Janssen-Cilag. AC: grant support, advisory board fees, research funding, and/or consulting fees from Takeda, Celgene, Novartis, Amgen, Janssen, BMS, Sanofi, Oncopeptides, Pharmacyclics, Seattle Genetics, Array BioPharma. DV: consulting, research funding, and/or advisory role Celgene, Amgen, Karyopharm, Teva, Janssen, Millennium, Acetylon, GlaxoSmithKline, Calithera Biosciences, Constellation. AJ: research funding, honoraria, consulting, and/or advisory role Karyopharm, Amgen, Abbvie, Celgene, Janssen, Takeda, Sanofi, SkylineDx. DD: research funding Takeda, Karyopharm. CH: grant or personal fees Janssen, Celgene, Karyopharm, Oncopeptides, Adaptive Biotechnologies. DS: speakers’ bureau and/or funding: Celgene, Amgen, Janssen, Takeda, BMS. DW: consultancy fees and honoraria Amgen, Celgene, Janssen, Sanofi, Takeda. SL: advisor and/or shareholder Caelum Biosciences, Janssen, Bayer. CAH: fees/travel/advisory/and/or grant support Janssen, Celgene, Sanofi, Karyopharm, Glenmark. SJ: advisory or consulting fees Celgene, BMS, Janssen, Merck. RB: consulting, advisory role, and/or funding Celgene, Karyopharm, Signal Genetics, Takeda, Merck. AN: advisory board fees Amgen, GlaxoSmithKline, BMS, Celgene, Takeda, Janssen, Spectrum, Adaptive Biotechnologies. JR: consulting fees and speakers bureau Amgen, Celgene, Takeda, Janssen, Sanofi, Karyopharm, Oncopeptides, Adaptive Biotechnologies, and BMS. RA: honoraria, consulting, advisory role, and/or speaker’s bureau Celgene, Amgen, Takeda, Janssen, BMS, Karyopharm. AY: consulting fees or grant support Adaptive Biotechnologies, Amgen, Karyopharm, Takeda, Janssen, Dexcel Pharma, BMS, Celgene. PM: honoraria Janssen, Celgene, Takeda, Amgen, and AbbVie. SL: advisory board fees Celgene, Takeda, Janssen, Novartis, BMS, and GlaxoSmithKline. ST: consulting/speaker’s bureau/advisory board or grant support Celgene, Amgen, Janssen, Sanofi, Merck, Alnylam. KW: honoraria/consulting/advisory role/funding Amgen, BMS, Celgene, Janssen, Novartis, Onyx, Takeda, Sanofi. MM: grant support/fees Janssen, Sanofi, Jazz Celgene, BMS, Takeda Amgen, Roche. TU, KL, YC, LL, JS, SS, MK: employees/stockholders in Karyopharm. SS: Founder/President/CSO Karyopharm. MK: CEO Karyopharm. MD: honorarium/consulting/advisory role/funding Amgen, Novartis, Celgene, Takeda, Genesis, Janssen, BMS. The remaining authors report no relevant conflicts of interest.